IPO for G1 Therapeutics

$15.00 (Est. Date 05/17/2017)

  • G1 Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer
  • G1’s two clinical assets are based on G1’s core understanding of cyclin-dependent kinaseos, or CDKs, a family of proteins that play an important role in the growth and proliferation of all human cells
  • G1 has leveraged their deep expertise in CDK4/6 biology to discover and develop two highly potent and selective CDK4/6 inhibitors that may have broad applicability across multiple cancer indications.
  • G1 is the only company with two distinct clinical-stage CDK4/6 inhibitors, trilaciclib and G1T38, each of which has the potential to be the backbone therapy of multiple combination regimens.

Show More
This information has been gathered from the company's offering prospectus.

IPO Documentation

Loading...

Key IPO Data

GTHX
NASDAQ
$122,187,500
6,250,000
J.P.Morgan
This information has been gathered from the company's offering prospectus.

How Does an IPO Work?

Open a Motif Account

Open a brokerage account to get ready for trading.

Participate in an IPO

Review IPO pricing, prospectus, and other documentation.

Place a Conditional Order

Select an investment amount and fund the IPO.

Receive Your IPO Shares

View your allocated shares on account positions page.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given after the effective date.